SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

This Morning's Technical Outlook on Application Software Stocks -- Paycom Software, Proteostasis Therapeutics, RealPage, and Red Hat
[February 08, 2018]

This Morning's Technical Outlook on Application Software Stocks -- Paycom Software, Proteostasis Therapeutics, RealPage, and Red Hat


NEW YORK, Feb. 8, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on PAYC, PTI, RP, and RHT which can be accessed for free by signing up to www.wallstequities.com/registration. On Wednesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.90%; the Dow Jones Industrial Average edged 0.08% lower; and the S&P 500 was down 0.50%. US markets made broad based losses with seven out of nine sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Application Software stocks: Paycom Software Inc. (NYSE: PAYC), Proteostasis Therapeutics Inc. (NASDAQ: PTI), RealPage Inc. (NASDAQ: RP), and Red Hat Inc. (NYSE: RHT). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration

Paycom Software

Oklahoma City, Oklahoma headquartered Paycom Software Inc.'s stock finished Wednesday's session 2.44% lower at $84.50. A total volume of 2.01 million shares was traded, which was above its three months average volume of 602.51 thousand shares. The Company's shares have advanced 86.12% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.37% and 12.82%, respectively. Furthermore, shares of Paycom Software, which provides cloud-based human capital management software solution that is delivered as software-as-a-service for small to mid-sized companies in the US, have a Relative Strength Index (RSI) of 43.77.

On February 07th, 2018, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $85 a share to $90 a share. Get the full research report on PAYC for free by clicking below at: www.wallstequities.com/registration/?symbol=PAYC

Proteostasis Therapeutics

Shares in Cambridge, Massachusetts headquartered Proteostasis Therapeutics Inc. ended at $2.80, down 2.78% from the last trading session. The stock recorded a trading volume of 519,980 shares. The Company's shares have gained 62.79% over the previous three months. The stock is trading below its 50-day moving average by 34.53%. Moreover, shares of Proteostasis Therapeutics, which engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis, have an RSI of 35.36. PTI's complimentary research coverage is a few simple steps away at: www.wallstequities.com/registration/?symbol=PTI

RealPage

Richardson, Texas headquartered RealPage Inc.'s stock ended yesterday's session 1.24% higher at $49.05 with a total trading volume of 461,104 shares, which was above its three months average volume of 455.00 thousand shares. The Company's shares have advanced 12.37 over the previous three months and 52.80% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 6.12% and 19.58%, respectively. Additionally, shares of RealPage, which provides software and data analytics for the real estate industry in the US, have an RSI of 56.16.

On January 30th, 2018, research firm Morgan Stanley upgraded the Company's stock rating from 'Equal-Weight' to 'Overweight'. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RP at: www.wallstequities.com/registration/?symbol=RP

Red Hat


On Wednesday, shares in Raleigh, North Carolina headquartered Red Hat Inc. recorded a trading volume of 1.46 million shares. The stock finished the day 0.10% higher at $128.81. The Company's shares have advanced 63.34% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.23% and 18.33%, respectively. Furthermore, shares of Red Hat, which provides open source software solutions to develop and offer operating system, virtualization, management, middleware, cloud, mobile, and storage technologies to various enterprises worldwide, have an RSI of 53.08.

On January 24th, 2018, research firm Nomura initiated a 'Buy' rating on the Company's stock, with a target price of $152 per share. Aspiring Member, please take a moment to register below for your free research report on RHT at: www.wallstequities.com/registration/?symbol=RHT

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

Cision View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-application-software-stocks----paycom-software-proteostasis-therapeutics-realpage-and-red-hat-300595697.html

SOURCE Wall St. Equities


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy